DAY ONE BIOPHARMACEUTICALS I (DAWN)
Institutional ownership reported to the SEC as of Q2 2026, across 21 quarters.
1
Reporting holders
$3.6K
Reported value
0.0%
Held as options
-206
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| IFP Advisors, Inc | $3.6K | 165 | 0.00% | 12q | -74.2%-$10.2K |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $3.6K | 165 | 0 | 0 | 1 | 0.0% |
| Q1 2026 | 207 | $1.8B | 81,913,955 | 82 | 60 | 44 | 4.6% |
| Q4 2025 | 175 | $763.0M | 80,929,989 | 41 | 66 | 42 | 1.8% |
| Q3 2025 | 165 | $601.6M | 86,540,927 | 31 | 53 | 57 | 0.1% |
| Q2 2025 | 165 | $551.9M | 85,588,765 | 24 | 68 | 53 | 0.3% |
| Q1 2025 | 172 | $737.0M | 92,952,995 | 39 | 68 | 38 | 0.4% |
| Q4 2024 | 154 | $1.2B | 91,218,240 | 20 | 56 | 36 | 0.4% |
| Q3 2024 | 158 | $1.3B | 89,523,588 | 30 | 62 | 34 | 0.4% |
| Q2 2024 | 146 | $1.0B | 72,298,654 | 29 | 44 | 46 | 0.7% |
| Q1 2024 | 138 | $1.1B | 69,274,419 | 23 | 45 | 36 | 0.2% |
| Q4 2023 | 128 | $1.1B | 72,781,797 | 15 | 46 | 27 | 0.2% |
| Q3 2023 | 120 | $900.8M | 73,334,584 | 11 | 49 | 31 | 0.2% |
| Q2 2023 | 125 | $881.2M | 73,599,024 | 37 | 54 | 19 | 0.3% |
| Q1 2023 | 107 | $873.4M | 65,233,897 | 27 | 35 | 21 | 0.2% |
| Q4 2022 | 88 | $1.2B | 55,207,625 | 22 | 26 | 19 | 0.6% |
| Q3 2022 | 91 | $1.2B | 60,764,774 | 22 | 33 | 15 | 0.6% |
| Q2 2022 | 88 | $1.1B | 59,382,061 | 38 | 28 | 16 | 1.0% |
| Q1 2022 | 66 | $429.6M | 43,302,427 | 17 | 20 | 13 | 0.0% |
| Q4 2021 | 57 | $707.6M | 42,033,341 | 14 | 25 | 4 | 0.0% |
| Q3 2021 | 45 | $452.9M | 19,096,008 | 20 | 10 | 7 | 0.0% |
| Q2 2021 | 32 | $418.3M | 18,480,886 | 32 | 0 | 0 | 0.0% |